FDA approves new drug Rocklatan to reduce intra-eye pressure in open-angle glaucoma or high-eye pressure patients
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recent, the United StatesThe FDA(http://approved thenew drug(http://Rocklatan to reduce intra-eye pressure (IOP) in patients with open-angle glaucoma or hyper-eye pressureRocklatanRocklatan is a daily eye drop, consisting of 0.02% Ofarsuda (Netarsudil) and 0.005% Pga LatanoprostIn mercury 1 and MERCURY 2 two Phase 3 clinicaltrial(http://, Rocklatan reached the main end of the trial (90-day efficacy) and had a better single effect than Netarsudil and Latanoprost, with significant eye pressure reductionMore than 60 percent of patients reduced eye pressure by 30 percent or more, which was about twice as much as using Latanoprost aloneIn two MERCURY studies, patients treated with Rocklatan had the least systemic side effects, with more mild and tolerable eye adverse eventsamong, the most common adverse eye events are conjunctiva congestion, 90% of hyperemia patients are mild congestion, 5% of patients due to hyperemia and discontinuation of drugsOther common eye side effects reported in the study included pain at the drip site, conjunctiva bleeding, and so on
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
